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Abstract
Background: Parkinson's disease, for which currently there is no cure, develops as a result of
progressive loss of dopamine neurons in the brain; thus, identification of any potential therapeutic
intervention for disease management is of a great importance.
Results: Here we report that prophylactic application of water-soluble formulation of coenzyme
Q10 could effectively offset the effects of environmental neurotoxin paraquat, believed to be a
contributing factor in the development of familial PD. In this study we utilized a model of paraquat-
induced dopaminergic neurodegeneration in adult rats that received three weekly intra-peritoneal
injections of the herbicide paraquat. Histological and biochemical analyses of rat brains revealed
increased levels of oxidative stress markers and a loss of approximately 65% of dopamine neurons
in the substantia nigra region. The paraquat-exposed rats also displayed impaired balancing skills on
a slowly rotating drum (rotorod) evidenced by their reduced spontaneity in gait performance. In
contrast, paraquat exposed rats receiving a water-soluble formulation of coenzyme Q10 in their
drinking water prior to and during the paraquat treatment neither developed neurodegeneration
nor reduced rotorod performance and were indistinguishable from the control paraquat-untreated
rats.
Conclusion: Our data confirmed that paraquat-induced neurotoxicity represents a convenient rat
model of Parkinsonian neurodegeneration suitable for mechanistic and neuroprotective studies.
This is the first preclinical evaluation of a water-soluble coenzyme Q10 formulation showing the
evidence of prophylactic neuroprotection at clinically relevant doses.
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Background
Parkinson's disease (PD), one of the common neurode-
generative disorders, results from progressive loss of
dopamine (DA) neurons in the substantia nigra pars com-
pacta (SNpc). More than 95% of PD cases are sporadic and
the disease often begins after the age of 60 years [1,2].
Symptoms, such as resting tremors, postural instability,
rigidity and bradykinesia, become marked upon the loss
of approximately 80% of the DA neurons. Along with
these motor deficits, PD patients exhibit loss of balance
that may be implicated in their impaired ability to volun-
tarily change gait stride or direction and their psychologi-
cal fear of falling [3].
Although the exact causes of sporadic PD remain unclear,
numerous environmental risk factors, especially neuro-
toxins, have been implicated in its etiology [4]. Environ-
mental toxins such as rotenone, maneb (MB) and
paraquat (PQ, 1,1-dimethyl-4,4-bipyridinium) have been
shown to induce PD-like symptoms in experimental ani-
mals [5]. A recent study of an East Texas population that
used a case-control design revealed an elevated risk of PD
from exposure to organic pesticides such as rotenone and
paraquat [6]. Experimental evidence of the neurotoxicty
of such organic compounds has been demonstrated in
mice and rats. Exposure to PQ alone or in combination
with MB in such animals has been shown to result in loss
of DA neurons in SNpc and to reduce the animals' general
activity [7-10].
The chemical structure of PQ is similar to the known
dopaminergic neurotoxin, N-methyl-4-phenylpridinium
ion (MPP+), the active metabolite of MPTP. Thus, it
belongs to the class of redox cycling compounds capable
of inducing mitochondrial damage, increase ROS produc-
tion and oxidative stress [11,12]. Ultimately, it may be
important to develop an animal model of PD that consists
of sensitive behavioural indicators of early onset of DA
neurodegeneration in the SNpc and to test the effective-
ness of any neuroprotective agents. Obviously application
of such a substance during the early stage of PD in
humans could help them maintain a normal quality of
life. Rather than examining the effects of any neuro-pro-
tective agent on maintenance of animals' general activity,
one should investigate its effects on more sensitive behav-
ioral indicators such as balance and gait performance.
Wishaw et al. (2003) devised a rotorod test for examining
impaired gait performance of rats exposed to near com-
plete unilateral destruction of the substania nigra [13].
They found that such rats exhibited contra-lateral inflexi-
ble digit extension and a general hunched posture when
forced to walk on a slowly rotating (12 R.P.M.) drum
("rotorod"). Less severe but more general destruction of
the substantia nigra in these animals might produce less
dramatic and more specific effects due to reduced balance.
That is, such animals would be expected to show less
spontaneous variability in maintaining their balance on
the rotorod.
Oxidative stress burden in the midbrain is usually high
even under normal conditions, due to generation of reac-
tive metabolites of DA, and is further elevated in PD
patients [11]. Currently there is no cure for PD, however,
there is an ongoing search for reliable neuroprotectants
that could diminish the rate of neurodegeneration and
help patients maintain a better quality of life. Thus, agents
capable of improving the mitochondrial function and
inhibiting oxidative stress should provide neuroprotec-
tion [14]. To this effect, antioxidants such as vitamin E
and Coenzyme Q10 (CoQ10) have been extensively evalu-
ated in both preclinical animal studies and clinical trials
[15-18]. CoQ10, especially, continues to attract attention
as it is not only a critical component of the mitochondrial
respiratory chain complexes, it is also a powerful antioxi-
dant [19]. Its clinical applications, however, show a low
efficacy, probably because of its lack of solubility in aque-
ous media and poor bioavailability. A recently developed
water soluble formulation of CoQ10  (WS-CoQ10)
addresses these issues to offer potentially greater benefits
and a wider range of applications [20]. This WS-CoQ10
formulation protects neuronal cells in vitro from gluta-
mate excitotoxicity [21] and direct oxidative stress [22]. It
is also effective in mitigating the brain damage caused by
ischemia in experimental rats [23].
Previously, we have shown that PQ causes mitochondrial
dysfunction and apoptosis in differentiated human neu-
roblastoma cells and that pretreatment of cells with WS-
CoQ10 offers neuroprotection [24]. Here we describe a
model of PQ-induced neurodegeneration in adult Long
Evans hooded male rats and the application of WS-CoQ10
in drinking water to offset such toxicity. Using histologi-
cal, biochemical and behavioural assessments, we estab-
lished that systemic exposure of rats to PQ caused
oxidative stress, loss of DA neurons in SNpc, and affected
the animals' motor skills, as evidenced by a reduced vari-
ability in balancing on a rotorod. More importantly, we
found neuroprotection and amelioration of these PD-like
behavioral symptoms in rats given WS-CoQ10 in their
drinking water.
Methods
Water-soluble formulation of CoQ10 (WS-CoQ10)
Water-soluble formulation was prepared from CoQ10
(Kyowa Hakko, New York, NY) and polyoxyethanyl α-
tocopheryl sebacate (PTS) by directly combining both
components in a molar ratio of 1: 2 mol/mol (1: 3 w/w)
and heating them to a temperature higher than their
respective melting points to form a clear melt, which is
water-soluble and can be diluted with aqueous solutionsBMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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(e.g., water, saline, phosphate buffered saline) to a desired
concentration. PTS was synthesized by conjugating poly-
ethylene glycol 600 to α-tocopherol via bi-functional
sebacic acid (Sigma-Aldrich, St. Louis, MO) as previously
described [20]; http://www.Zymes.com.
Typically, stock solutions of WS-CoQ10 (50 mg of CoQ10
and 150 mg of PTS per ml in PBS (phosphate buffered
saline) or a placebo (150 mg of PTS per ml of PBS) were
made and stored at 4°C. They were subsequently diluted
with regular drinking water to a final concentration of 50
μg CoQ10 and 150 μg PTS per ml (WS-CoQ10) or 150 μg
PTS per ml (placebo).
Experimental animals and their general care
All animal care, treatments, and procedures were
approved by the University of Windsor's Animal Care
Committee in accordance with the Canadian Council for
Animal Care guidelines. A total of forty-seven adult male
Long-Evans hooded rats purchased from Charles River
Laboratories (St. Canstant Quebec). The rats were approx-
imately 3.0 months old at the start of the experiments.
Rats were housed in group cages (3–4 rats per cage) daily
except during 2 hours afternoon feeding times, in accord-
ance with Canadian Government animal care guidelines
for long-term maintenance. In view of this requirement,
rats in each cage had to receive the same specific drinking
water regimen and injection condition in order to sepa-
rate saline-injected from paraquat injected animals. This
was necessary to prevent the development of any domi-
nance hierarchies based on degree of neurodegeneration.
Otherwise, saline-injected or other neuroprotected rats
might become dominant over their cage mates subjected
to neurodegeneration and thus gain more access to food
and liquids. However, it is important to note that group
caging of rats with the same liquid and injection condi-
tions, is not sufficient a guarantee against the develop-
ment of dominance hierarchies that is normal in such
social animals. Thus the possibility would remain that less
dominant animals might not gain equal nutritional
access. In order to avoid this, we also instituted a separate
2 hour feeding schedule every afternoon, where each ani-
mal was isolated in an individual holding cage and pro-
vided 25 g of dry rat chow and its specific liquid
treatment. These maintenance procedures insured that
rats consumed enough food to insure normal weight gain
over the course of the experiment from their starting
weights of 300–320 g to 410–450 g by the end of the
experiment. This feeding schedule also promoted drink-
ing further insuring that each rat received its normal daily
amount of liquid. Drinking solutions (regular water,
water supplemented with WS-CoQ10 or with the placebo
carrier solution) were always available in group and indi-
vidual holding cages but food was only available in the
individual cages. Water bottles containing WS-CoQ10 and
placebo were covered with aluminium foil and all bottles
were refilled every three days. The animal colony room
was maintained on a reversed 12 h:12 h light: dark cycle
with the temperature maintained at 20°C. Our study con-
sisted of two separate experiments (figure 1A–B)
described as follows.
Experiment 1
This experiment was designed to determine whether the
original paraquat (PQ) injection protocol used with mice
[7] could produce similar neurodegenerative effects in
Long-Evans hooded rats, and if so, whether WS-CoQ10
supplement in their drinking water could offer any protec-
tion from the toxic effects of paraquat. This experiment
initially contained twenty naïve adult male Long-Evans
hooded rats, partitioned into four separate groups, of
which two received plain drinking water, one received
drinking water supplemented with WS-CoQ10, and the
other received drinking water supplemented with the car-
rier solution (Placebo) throughout the course of the
experiment (Figure 1A). Since placebo (also called PTS in
our study) is a pro-drug form of vitamin E (in which toco-
pherol was chemically derivatised by sebacic acid and
PEG) and is used as a component (carrier) in WSCoQ10
formulation [23], the possible neuroprotective effects of
CoQ10 were compared to placebo and water groups. After
two weeks from the beginning of their respective drinking
water treatments, rats were given 3 weekly intraperitoneal
injections of saline or paraquat (10 mg/kg body weight
dissolved in PBS). One group that received plain drinking
water was injected with saline (Saline-Water group). The
other three groups were injected with paraquat (PQ-Water
group; PQ-Placebo group; PQ-CoQ10 group). One week
after their last injection, rats were perfused with
heparinised tyrode's solution (pH 7.4) followed by 10%
neural buffered formalin and sacrificed. Brains were
removed and fixed in 10% buffered formalin for another
12 h and embedded in paraffin for histochemical analysis.
We note that technical difficulties prevented accurate
assessment of TH-positive neurons in the Saline-Water
group. Therefore, we added two more age-matched ani-
mals from the same colony to this group for further assess-
ment.
Experiment 2
This experiment was designed not only to conduct histo-
logical/biochemical assays of PQ-induced neurodegener-
ation, but also to analyze a potential PD-like behavioural
changes resulting from such exposure (Figure 1B). In
addition, we intended to determine whether WS-CoQ10
treatment could offset PQ-induced behavioural impair-
ment. In view of the fact that no differences occurred
between the PQ-Placebo and PQ-Water treatment groups
in Experiment 1, we eliminated plain water treatment, but
gave animals either WS-CoQ10 or its carrier solution PTS
(Placebo) in their drinking water. We used twenty-five
naïve adult male Long-Evans hooded rats for this experi-BMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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ment and exposed them to the same basic injection sched-
ule as in Experiment 1. Twelve animals always received
drinking water supplemented with the WS-CoQ10 and
were divided into two equal injection groups (Saline-
CoQ10 and PQ-CoQ10). The other 13 rats always received
the placebo supplemented drinking water and were also
divided into two groups based on the injection regime,
resulting in the Saline-Placebo group (6 animals) and the
PQ-Placebo group (7 animals). Rats were sacrificed two
weeks after the last injection, as opposed to one week after
the last injection in experiment 1. This added week
allowed us to carry out post-injection behavioural assess-
ments of gait performance on the rotorod.
Behavioural assessment
Rotorod Apparatus
We measured rats' ability to maintain their balance on a
rotorod as per a previously described protocol [13]. This
rotorod apparatus consisted of a paper-covered (80 grid)
15 cm long, 7 cm diameter wooden dowel attached to a
variable speed motor. Clockwise revolutions of the
rotorod could be adjusted from 6 to 12 R.P.M. The rod
was separated from the motor by a vertical 30 × 48 cm
Schematic outlines of experimental procedures Figure 1
Schematic outlines of experimental procedures. A) Experiment 1: Four experimental groups of animals were provided 
with indicated water or water supplemented with placebo or WS-CoQ10. Three weeks later, they received intraperitoneal 
injections (open circles) of saline or PQ (10 mg/kg) once a week for 3 consecutive weeks. One week following the last injection 
(dark arrow), rats were sacrificed and brain tissue was collected for immunohistochemical studies. B) Experiment 2: Four 
experimental groups of animals were given either placebo or WS-CoQ10 supplemented drinking water (as indicated). Three 
weeks later, they received intraperitoneal injections (open circles) of saline or PQ (10 mg/kg) once a week for 3 consecutive 
weeks. Rats were trained on the rotorod during the pre-injection period (grey arrowheads) and behavioural assessment was 
conducted on the third, fourth and fifth rotorod sessions (dark arrowhead). Two weeks following the last injections, rats were 
sacrificed and brain tissue was collected for biochemical studies (dark arrow).BMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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grey wooden panel that was scored with black vertical and
horizontal lines to form 12 × 12 cm squares as shown in
Figure 4B. The apparatus rested on a small table so that the
dowel was 27 cm above its surface. A digital video camera
(Orbyx Electronics Inc, CA) was positioned 1 m in front
of and level with the rod. The apparatus was illuminated
by regular fluorescent ceiling lighting and a 60-W lamp
approximately 3 m in front of it.
Experimental procedure
Experiment 2 setup consisted of a two week pre-injection
phase followed by an injection phase of three weeks and
a two-week post-injection phase. Rats received three
rotorod sessions during the pre-injection phase, spaced
approximately two days apart over the two-week period,
one rotorod session five days after the second injection
(mid-injection test), and one session in the post-injection
phase given one week after their last injection. The first
two pre-injection sessions served to train the rats to main-
tain their balance on the rotorod while we gradually
increased its rotation speed from 6 to 12 R.P.M. From the
third test on, we maintained the rotorod's rotation speed
at 12 R.P.M. Rats' performance on the third pre-injection
test provided baseline performance for comparison with
the next two tests. Rats were always placed in the forward
position (facing left) as the rod rotated clock-wise.
Dependent Behavioural Measures and Statistical Analyses
Each rat's video recording was converted to 5 frames per
second still pictures from which we recorded its move-
ments over the last 100 seconds (500 frames) with a soft-
ware tracking program (7 Software, Inc, Montana, U.S.A.).
Figure 4B illustrates a picture frame superimposed on the
tracking frame composed of 450 vertical and 450 horizon-
tal pixels. It was noted that although rats were initially ori-
ented to walk forward on the slowly rotating rotorod, they
also turned around and walked backward during some
portions of these sessions. Therefore, we calculated the
amount of time each rat actually spent (proportion of
frames) walking backward as well as its average horizontal
and vertical nose locations as it walked in each direction.
Each rat's proportion of time spent walking backward was
transformed into an arcsin 2√X measure to enhance
homogeneity of variance for parametric statistical analysis
of proportion scores [25]. Each dependent measure was
analyzed by 2 (Injection: PQ vs. Saline) by 2 (Liquid Sup-
plement: CoQ10 vs. Placebo) by 3 (Rotorod Test Session:
pre-, mid-, post-injection) analysis of variance (ANOVA)
with repeated measures on the last factor. We conducted
statistical analyses of the behavioural data with SPSS (ver-
sion 17) program and report significant effects at p < .05.
Immunohistochemistry
Rats from experiment 1 (Figure 1A) were perfused with
heparinised tyrode's solution (pH 7.4) followed by 10%
neural buffered formalin and sacrificed. Brains were
removed and fixed in 10% neural buffered formalin for
another 12 h and embedded in paraffin. Coronal sections
(8 μm) were cut across the whole substantia nigra region
and processed for immunohistochemistry using a stereo-
taxic rat brain atlas. Briefly, sections were deparaffinized
and incubated with Tris-buffered saline (TBS: 50 mM Tris-
HCl, 150 mM NaCl, pH 7.6) containing 3% H2O2 for 10
min at room temperature to destroy endogenous peroxi-
dise activity. Nonspecific IgGs were blocked with univer-
sal blocking solution (DAKO diagnostics Canada Inc.,
Mississauga) for 30 min at room temperature. Excess liq-
uid was drained, and sections were incubated in a humid
chamber with a rabbit polyclonal anti-tyrosine hydroxy-
lase antibody (1:1000 Pel-Freeze Biologicals, USA) for 24
h at 4°C. Negative controls included the omission of pri-
mary or secondary antibodies. Sections were then washed
in TBS and incubated with DAKO Envision peroxidase
conjugated to goat anti-rabbit IgG for 30 minutes at room
temperature. Immunolabelling was detected using 0.02%
diaminobenzidine tetrachloride and 0.006% hydrogen
peroxide for 10 min at room temperature. Sections were
washed in running water and then counterstained with
Mayer's hematoxylin. The images were captured using a
Carl Zeiss Axiovert 200 M microscope. The loss of
dopaminergic neurons was determined by counting TH-
immunopositive cells (cell body) under bright-field illu-
mination. After delineation of the SN pars compacta using
the 10H objective, every 5th section from the entire sub-
stantia nigra region (a total of 15–20 slides) was counted
using 20H objective and the average of all counts repre-
sented the total number of neurons per section. Multiple
sections were counted to obtain the TH+ve neuronal
numbers. The entire region from the beginning to end was
scanned.
Tissue fractionation
In both experiments rats designated for biochemical
assays were sacrificed by CO2 inhalation and their brains
were removed. These isolated brains were washed with
ice-cold PBS and placed on ice until further dissection.
Midbrain region was dissected, weighed and homoge-
nized in an ice-cold isolation medium (50 mM Tris-HCl,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM benza-
midine, 10 μg/ml pepstatin A and 10 μg/ml leupeptin; 5
ml buffer/1 g tissue). The homogenates were centrifuged
at 500 × g for 10 min. The pellets were discarded and the
supernatant was used as the cytosolic fraction in all subse-
quent assays. Protein content was measured using the Bio-
Rad assay.
Glutathione assay
Three rats from each group in Experiment 2 were desig-
nated for the GSH assay. This assay was performed essen-
tially as previously described [26]. Briefly, 50 μl of
cytosolic fraction (obtained from the midbrain) and 100BMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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μl of reaction mixture (1 mM NADPH, 100 mM
Na2HPO4, 100 units GSH reductase and 1 mM DTNB)
were incubated for 15 min at 37°C in a 96 well plate.
Absorbance was measured at 412 nm using a Bio-tek ELx
808 ru Ultra Micro Plate Reader. GSH levels were deter-
mined from the standard curve constructed using 1 mM
GSH. Levels of GSH were expressed per microgram pro-
tein.
Lipid Peroxidation Assay
Two rats from each group in Experiment 1 were desig-
nated for the lipid peroxidation assay. It was performed as
previously described [27]. Briefly, 100 μl of the cytosolic
fraction of the midbrain was added to 1 ml of thiobarbi-
turic acid and incubated at 100°C on a heat block for 20
min. After cooling the tubes, absorbance was measured at
535 nm (Genesys spectrophotometer). Lipid peroxidation
levels were determined from the standard curve prepared
using 1 mM malondialdehyde (MDA). Lipid peroxidation
levels were expressed per microgram protein.
Statistical analysis
Unless otherwise stated, all the biochemical experiments
have been performed in triplicates in 3 animals, but TH
counting was performed by the counting 10 slides for
each animal and three separate animals were used for
counting. One-way analysis of variance (ANOVA) fol-
lowed by post-hoc Bonferroni's multiple comparisons test
was used to assess statistical differences. Significant effects
at P < 0.05 are reported. Statistical tests were performed
using GraphPad Prism version 4.0.
Results
The effects of PQ and WS-CoQ10 on DA neurons in the 
midbrain
Microscopic examination of midbrain sections revealed
reduced TH immunostaining in the PQ-injected rats (both
water and placebo-fed groups, Figure 2B and 2C, respec-
tively) as compared to the control saline-injected rats (Fig-
ure 2A). There was also a diminished staining of TH-
positive fibres, indicative of neuronal loss and reduced
density of the fibres (compare Figure 2B-b' and 2C-c' to
2A-a'). These PQ-injected animals received either regular
drinking water or placebo throughout the duration of the
experiment. In striking contrast were the images of the
PQ-WS-CoQ10 midbrain sections, which showed a strong
TH immunostaining of both the cell bodies and the fibres
(Figure 2D and 2D-d'). This group of rats was given the
WS-CoQ10 supplemented drinking water, which might
have counteracted the effects of PQ. The immunostaining
data was confirmed by counting the TH -positive cells in
the entire region of SNpc (Figure 2E). The TH -positive
cells results were expressed as percent control. The counts
revealed a nearly 65% reduction of the cell number in the
PQ-injected rats receiving regular drinking water (from
313.7 ± 11.3 in Saline group to 110.33 ± 8.5 in PQ-pla-
cebo group, P < 0.001) and 60% reduction in the placebo
fed group (down to 121.33 ± 2.081). The cell counts also
confirmed the neuroprotective effects of WS-CoQ10.
Although the estimated number of TH-positive neurons
in PQ-WS-CoQ10 group was lower than in control saline
group, their total number was still 2.5-fold higher than in
PQ-water group (P < 0.001) and 1.5 times higher than in
PQ-WS-placebo group (P  < 0.001). Interestingly, the
counts also revealed a higher number of TH-positive cells
in PQ-Placebo group in comparison to PQ-Water group
(P < 0.001). It should be noted here that the placebo solu-
tion contained PTS, a derivatised form of vitamin E, which
could be responsible for this neuroprotection.
Assessment of oxidative stress markers
We measured the GSH content (Figure 3A) and lipid per-
oxidation (Figure 3B) in the midbrain of experimental
animals as the markers of oxidative stress. We compared
the levels of these markers in the brains of PQ-injected
groups (Placebo and WS-CoQ10  fed groups) with the
saline injected groups (Placebo and WS-CoQ10  fed
groups).
GSH is an abundant antioxidant in many tissues, includ-
ing the brain and is known to protect cells against oxida-
tive damage [28,29]. Depletion in GSH levels has been
observed in the MPTP model of PD [30]. In this study, the
GSH content in the PQ-placebo group was reduced by half
as compared with the saline groups (P < 0.001), consist-
ent with it being utilized to combat the effects of PQ (Fig-
ure 3A). However, the GSH level was maintained at nearly
control level in the PQ-WS-CoQ10  group (Comparing
both the paraquat injected groups, P < 0.001), suggesting
that the antioxidant content of WS-CoQ10 formulation
offsets the effect of PQ, sparing the GSH system.
Recent studies report a higher malondialdehyde (MDA)
level [31] and increased lipid peroxidation in the substan-
tia nigra region of PD-exposed brains [32]. Here we meas-
ured the content of MDA, the product of lipid
peroxidation, to assess the degree of PQ-induced lipid
damage (Figure 3B). The data showed that the damage
was particularly evident in PQ-water group as indicated by
a significantly increased MDA level in comparison to
groups injected with paraquat and fed with either placebo
or WS-CoQ10 (P < 0.05). Again, the MDA level in PQ-WS-
CoQ10 was nearly the same as in the saline injected groups
and it was significantly lower than in the PQ-placebo
group (P < 0.05). Thus, these results indicated that PQ
injections lead to the increased lipid peroxidation, which
was mitigated by WS-CoQ10.
In summary the biochemical and histological assessments
indicated that PQ injections induced oxidative stress inBMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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Immunohistochemical evaluation of midbrain damage Figure 2
Immunohistochemical evaluation of midbrain damage. Experiment1: Immunohistochemistry performed using anti-
tyrosine antibodies on the brain sections of animals. Representative photomicrographs of midbrain sections showing TH-
immunopositive neurons from saline injected animals (A), paraquat injected water fed animals (B), paraquat injected placebo 
fed animals (C) and paraquat injected WS-CoQ10 fed animals (D). Magnification: 10H. Insets (a' to d') show the density of TH-
immunopositive neurons and fibres in the respective groups. Magnification: 20×. (E) The number of TH-immunopositive neu-
rons counted in every fifth section throughout the substantia nigra pars compacta. Data are shown as mean ± SEM. Note: Signif-
icant differences (p < .001) ***between saline injected-water fed group and and paraquat injected water fed group; ### 
between saline injected-water feds and paraquat injected-placebo fed group; HHH between paraquat injected WS-CoQ10 fed 
group and paraquat injected placebo fed group (evidence of neuroprotection).BMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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the brain leading to lipid peroxidation, reduction of GSH
and 70% loss of TH positive neurons in the SNpc region.
The histological and biochemical assessments also
revealed that the toxicity of PQ towards DA neurons was
neutralized by the WS-CoQ10formulation.
Behavioural Assessments
As already noted, we subjected rats to a series of rotorod
tests over the course of Experiment 2 to measure sponta-
neous changes in their balancing behaviour. These neuro-
protective effects were accompanied by maintenance or
even improved balance on the rotorod (Figure 4A). In
fact, animals of the PQ injected WS-CoQ10 group behaved
the same on the rotorod tests as animals in either saline
injected groups.
Proportion of Time Spent in Walking Backward
Figure 4A shows the changes in the amount of time rats in
each group spent walking backward over the three test ses-
sions (pre-injection, mid-injection, post-injection).
Although all groups spent a greater proportion of their
time walking forward, they spent almost 30% to 40% of
their time walking backwards on their first (pre-injection)
test. Only rats in the PQ-Placebo group steadily reduced
the amount of time spent spontaneously walking back-
ward. Therefore during the post-injection test, they almost
exclusively maintained a forward walking gait. Rats in the
PQ-CoQ10 group showed an increased time spent walking
backward on the post-injection test as compared to those
in the PQ-Placebo group. The rats in the Saline-Placebo
group developed only slight declines, while those in the
Saline-CoQ10 group showed little if any change. The three-
way ANOVA on the transformed data uncovered a signifi-
cant injection type among all three factors, F (2, 42) =
4.68, p = 0.015. One-way within-subjects ANOVAs for
each group revealed that only rats in the PQ-Placebo
group significantly reduced their proportion of walking
backwards, F (2, 12) = 12.08. p < 0.01. There were no sig-
nificant effects for any changes in the other three groups.
Vertical and horizontal nose positions
Separate analyses of rats' vertical and horizontal nose
positions did not uncover any significant changes reflect-
ing the experimental treatments (i.e., PQ vs. saline injec-
tions or placebo vs. CoQ10 supplementation). As shown
in Figure 4B, rats tended to walk forward with their noses
slightly below the top of the rotorod (below the horizon-
tal line at 210 pixels) and extended well away from it (177
pixels from the left vertical line). When rats did walk back-
wards, they also tended to extend their noses similarly
slightly below the top of and away from the rotorod.
In summary, we found clear evidence of a motor balance
dysfunction in rats that had suffered paraquat-induced
neuronal loss in SNpc (PQ-Placebo group). These rats
drastically reduced their tendency to spontaneously turn
around and walk backwards during and following their
series of injections. On the other hand, paraquat-injected
Oxidative stress markers Figure 3
Oxidative stress markers. Experiment 2: Following 
behavioral testing, rats were sacrificed, midbrain tissue was 
homogenized and assayed for GSH (A) and MDA levels (B). 
Data (mean ± SEM) was normalized to that of saline injected 
placebo fed group, which was taken as 100%. (A) statistically 
significant differences (p < .001): *** between saline injected 
placebo fed group and paraquat injected placebo fed group; 
### between paraquat injected placebo fed group and saline 
injected WS-CoQ10 fed group; HHH between paraquat 
injected placebo fed group and paraquat injected WS-CoQ10 
fed group. (B) Statistically significant differences (p < .05): * 
between saline injected placebo fed group and paraquat 
injected placebo fed group; # between paraquat injected pla-
cebo fed group and saline injected WS-CoQ10 fed group; H 
between paraquat injected placebo fed group and paraquat 
injected WS-CoQ10 fed group.BMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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rats whose SNpc area was protected by WS-CoQ10 (PQ-
CoQ10 group) retained their pre-injection levels of the
backward gait on the final post-injection. Thus this group
did not differ statistically from either of the saline-injected
groups.
Discussion
Accumulated evidence suggests that PD may arise from a
combination of genetic susceptibility and exposure to
environmental toxins [32,4,33]. Indeed, several environ-
mental risk factors such as metals, solvents, carbon mon-
oxide and herbicides have been linked to the incidence
and progression of PD [34-37]. Amongst these factors, the
herbicide paraquat (PQ) shows clear neurotoxicity in the
central nervous system. PQ can enter the CNS through
neutral amino acid transporters associated with the blood
brain barrier system [38] and selectively damage the SNpc
neurons in mouse models [39]. It has also been reported
that a prolonged exposure to non-pneumotoxic levels of
PQ causes the damage to basal ganglia [33]. According to
the published data, a range of xenobiotics, including
paraquat and menadione, can undergo monoelectronic
redox cycling in isolated brain capillaries, giving a rise to
increased production of ROS [40,41]. Menadione, for
example, is shown to significantly increase the permeabil-
ity of endothelial cell monolayers in vitro [41]. Thus, there
is a correlation between free radical formation and passive
permeability of the cerebral microvascular endothelium;
therefore, it is possible that the neurotoxicity of PQ may,
in part, be linked to its ability to alter the permeability of
the blood brain barrier.
Our data clearly confirmed the toxicity of systemically
administered PQ, especially towards DA neurons of the
SNpc. Three weekly intraperitoneal injections of this her-
bicide effectively killed between 50–70% of DA neurons
in the midbrain of adult male Long-Evans hooded rats
and induced PD-like symptoms. The effectiveness of PQ
in killing DA neurons seems to vary from 40–70% in
reported experimental studies, but its selectivity towards
TH-positive neurons in the SNpc region is consitent in all
studies. Ossowska et al., (2005) showed that long term
paraquat administration caused somewhat less progres-
sive neuronal loss of about 37% loss of dopamine neu-
rons in adult male Wistar rats [42]. McCormack et al.,
(2002) found only about a 25% reduction in these DA
neurons in C57BL/6 mice [32]. However, Brooks et al.
(1999) found much greater losses of TH-positive neurons
in the substantia nigra pars compacta (~60%) and their
terminals in the striatum (~90%) after PQ exposure in
C57BL/6J mice given the same dosage used in our study
[7]. In the present study, we observed a loss of ~65%
dopaminergic neurons using a 3 injection PQ regime. Per-
haps, among other possible factors, the different strains of
mice and rats used in these two sets of studies may
account for the differences in susceptibility to PQ-induced
neuronal loss.
The question remains whether our rats may have simply
been susceptible to a more general, non-specific neurode-
generative effect from PQ exposure. Unfortunately, we did
not test for this possibility by examining other brain areas.
In view of this problem, we now use a general marker for
neurons namely NeuN to stain various areas of brain in
on-going experiments. Although we have yet to complete
this study, our preliminary results from those rats that
Behavioural Assessments Figure 4
Behavioural Assessments. Rats were trained on the 
rotorod and behavioural testing was carried out. A) Rats 
were placed on a moving rotorod and the time spent by the 
rats walking backwards on the rotorod was monitored. 
Measurements were made before (pre-injection), during 
(mid-injection) and after (post-injections) the PQ-injections. 
The data points represent the mean proportion of time 
spent walking backwards during each testing session B). Rep-
resentative image of the tracking format used for determin-
ing forward/backward walking posture as well as the location 
of nose on the rotorod. The horizontal line is positioned at 
the top of the rotorod and the two vertical lines determine 
the forward and backward walking positions. Any nose loca-
tions between the left and right vertical lines were not 
counted.BMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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have completed it, clearly show a clear decrease in NueN-
positive cell numbers in the midbrain area containing the
SNc region but no decline in NeuN immunostaining in
other areas of the brain; e.g. hippocampal region (data not
shown) following PQ injections. Therefore we are confi-
dent that PQ exposure targeted DA neurons of the SNpc.
Moreover, the affected rats showed clear signs of defi-
ciency in fine motor control as indicated by a reduced ten-
dency to turn around and walk backwards on the rotorod.
Furthermore, we have established that the brain damage
and the performance deficits could be minimized if not
prevented by giving the animals a water soluble formula-
tion of CoQ10 (WS-CoQ10) throughout the experiment.
This study is, in fact, the first pre-clinical evaluation of
WS-CoQ10 as a neuroprotectant of DA neurons.
The neurotoxicity of PQ is linked to its ability to destabi-
lize mitochondria and increase the production of reactive
oxygen species (ROS) [12]. Experimental evidence indi-
cates that PQ targets mitochondria of brain cells and the
affected mitochondria are a major source of ROS. Using
in-vitro assays, we show that PQ can destabilize the mito-
chondria isolated from mouse brains and from differenti-
ated human neuroblastoma cells [24], (Somayajulu et al.,
unpublished data). Furthermore ROS such as superoxide
reacts with nitric oxide to form reactive nitrogen interme-
diates, which impair the mitochondrial respiratory chain
and lead to decreased ATP synthesis [43]. Furthermore, we
found evidence of increased lipid peroxidation, which
could lead to changes in membrane properties and affect
cellular homeostasis [33]. Therefore, the evidence sug-
gests that dysfunctional mitochondria are most likely sig-
nificant contributors to PQ-induced neurotoxicity.
Our data has also shown that placebo offers some protec-
tion against oxidative stress; however, placebo alone is
not sufficient to protect the neurons from cell death
induced by paraquat. The placebo formulation consists of
Vitamin E and polyethylene glycol. Coenzyme Q10 on the
other hand, works at the mitochondrial level and does
prevents neuronal cell death induced by paraquat. Our
data adds to the mounting evidence that antioxidants,
especially CoQ10 and vitamin E, are important for the
management of neurodegenerative diseases [16]. Neuro-
protective effects of CoQ10 in the CNS have been exten-
sively evaluated [18,44] and several in vivo  studies
demonstrate its protective role against experimental
ischemia, sparing the levels of GSH and ATP [15,23].
CoQ10 is a highly hydrophobic, naturally occurring com-
pound that mainly functions in mitochondrial mem-
branes as a diffusible electron carrier for the
mitochondrial respiratory chain complexes. It is also a
powerful antioxidant readily scavenging free radicals [15].
Its pharmaceutical applications, however, seem to suffer
from the lack of solubility and low bioavailability, both
necessitating the applications of high doses to achieve a
therapeutic effect. An open-label phase I clinical trial of
CoQ10 in PD patients reveal a good absorption and toler-
ance of CoQ10, however, high dosages were required (up
to 1200 mg per day) to achieve some beneficial effects
[17,45]. A recent study by Cleren et al (2008) has shown
that oil soluble Tishcon CoQ10 formula provided signifi-
cant protection against MPTP toxicity in a mouse model
[18]. However the effective doses used in this work were
200 mg/kg/day-1600 mg/kg/day (equivalent to 14–114
gm/day for a 70 kg patient). This dose is also extremely
high and therefore unlikely to be used in human subjects.
On the other hand, the effective daily dose of the water
soluble formulation used in our study was 5 mg/kg/day in
rats, roughly one fourth of the dose used in the cited
above clinical trial and 40 times lower than the dose used
by Cleren et al (2008) in mice [18]. The results from our
study offer the possibility of using CoQ10 in smaller, clin-
ically relevant doses.
The water soluble formulation of CoQ10  has been
reported to be more efficacious as it combines two potent
antioxidants, i.e., derivatised vitamin E (PTS) and CoQ10
[23,20], http://www.Zymes.com. PTS is a pro-drug form
of vitamin E (alpha-tocopherol), which was chemically
derivatised by sebacic acid and PEG and used as a compo-
nent (carrier) in WSCoQ10 formulation [23]. These two
compounds form a stable and water soluble complex,
easy to deliver and test (i.e., in drinking water). The effec-
tive daily dose of this formulation that offered significant
neuroprotection in our study will translate to 350 mg/day
for a 70 kg human subject (roughly one fourth of the dose
used in the aforementioned clinical trial). Indeed rats fed
the WS-CoQ10  containing diet have shown elevated
plasma levels of CoQ10 [23]. Due to the water-soluble
nature of our formulation, we have done extensive work
on its effect as neuroprotective agent in neuronal cell cul-
tures [21,22,24]. In our previous in vitro studies we show
that this formulation of CoQ10  protects differentiated
SHSY-5Y cells against PQ toxicity by stabilizing mitochon-
drial membranes, maintaining mitochondrial membrane
potential and sustaining ATP production [24]. More
recently, we established that it inhibits Bax activity and
prevents Bax-induced destabilization of mitochondria in
mammalian cells [46].
Of equal importance in this study is the identification of
the fine behavioural abnormalities (indicative of altered
motor skills), observed in PQ-treated rats as the reduced
behavioural variability for balanced walking on the
rotorod (PQ-placebo group, Figure 4A). This was evi-
denced by rats reducing their spontaneous turning around
to walk backward. These PQ-injected rats were receiving
drinking water supplemented with derivatised vitamin EBMC Neuroscience 2009, 10:88 http://www.biomedcentral.com/1471-2202/10/88
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(PTS) as placebo and lost over 50% of the midbrain DA
neurons (Figure 2E). It should be noted, however, that the
rats of the PQ-Placebo group did not suffer extreme
behavioural motor dysfunction of slow ambulatory
behaviour with hunched postures, typically found in PD
patients. Such PD-like general ambulatory behaviour has
been observed in mice exposed to similar PQ and MPTP
dosages [7] and a forward rotorod gaiting in rats receiving
an unilateral destruction of the nigrostriatal bundle by tar-
geted injections of 6-hydroxydopamine [13]. These
behavioural differences, however, are not surprising given
the differences in level of SNpc destruction in our animals
compared with that of animals in the earlier studies.
Rats in the rotorod study described by Whishaw [13] obvi-
ously had most of their SNpc unilaterally destroyed which
also reduced their flexibility in fore- and hind limb paw
placement on the contralateral than ipsilateral side of the
damage. Given the more general, but lower degree of neu-
ronal loss in the PQ-Placebo group, it is not surprising
that we observed the same flexibility of their paw place-
ments as in the unaffected animals (both saline injected as
well as PQ-WS-CoQ10 fed groups). It is noteworthy that
symptoms of PD, such as resting tremors, postural insta-
bility, rigidity and bradykinesia, are not readily detectable
until individuals have more than 80% loss of their SNpc
neurons [11].
Conclusion
We have identified subtle behavioural deficits that accom-
panied substantially low losses of DA neurons (approx.
65%) in the SNpc region. The most obvious implications
of our results relate to the early detection of PD-like neu-
rodegeneration. Reduced behavioural variability in the
performance of simple motor or ambulatory tasks may
signal the early onset of this disorder in humans. Given
that CoQ10  or other neuroprotective agents can slow
down or even stop further reduction of neuronal popula-
tion, early detection and intervention could prevent fur-
ther development of the symptoms. Further research will
be required to establish the reliability and validity of such
subtle behavioural diagnostic measures.
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